Compare WNEB & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WNEB | ADAG |
|---|---|---|
| Founded | 1853 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.8M | 254.4M |
| IPO Year | 2001 | 2020 |
| Metric | WNEB | ADAG |
|---|---|---|
| Price | $14.10 | $3.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $13.67 | $8.25 |
| AVG Volume (30 Days) | 50.7K | ★ 366.1K |
| Earning Date | 04-28-2026 | 04-01-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | ★ 33.93 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $44,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.25 | N/A |
| P/E Ratio | $18.61 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.53 | $1.44 |
| 52 Week High | $14.52 | $4.75 |
| Indicator | WNEB | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 63.10 | 52.34 |
| Support Level | $13.60 | $3.49 |
| Resistance Level | $14.47 | $4.10 |
| Average True Range (ATR) | 0.31 | 0.23 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 62.37 | 67.44 |
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.